SYN2’s advantages
SYN2’s advantages
How does SYN2 differ from other radiopharmaceuticals?
Compared to other radiopharmaceuticals used in cardiology, SYN2 stands out for:
Its advantageous physical parameters
The possibility of centralized production and distribution to many facilities
The relatively simple and highly automated synthesis process
Great potential for technology transfer and implementation in various regions of the world
Compared to competing products, SYN2 offers a more favourable biodistribution profile as well as a less complex manufacturing process, which translates into both clinical and economic value.
Clinical benefits and diagnostic advantages
SYN2 offers a number of features making it a potential breakthrough in the diagnosis of coronary artery disease. The most important feature of radiotracers used in cardiology is the possibility of quantitative assessment of coronary flow in absolute units.
In SPECT examination, interpretation of the images is relative, based on a comparison of the patient’s results against the standard heart image. This can lead to underestimation of the extent of ischemia, as it is the most ischemic areas that are primarily captured.
By contrast, PET/CT examination using SYN2 enables an estimation of blood flow through each coronary artery, without the need for invasive catheterization. This facilitates:
- Better differentiation of patients who can be treated conservatively,
- Precise classification of persons requiring invasive procedures, such as angioplasty, stenting, or coronary artery bypass surgery.
This reduces the number of unnecessary coronary angiographies and revascularizations, which improves patient safety and reduces treatment costs.
Another key advantage of SYN2 is the high quality of the images obtained, compared to SPECT.
PET/CT examination using SYN2:
- Lasts a shorter time,
- Involves a lower dose of radiation,
- Offers higher-contrast images.
In clinical trials, the ratio of image quality to radiation dose was successfully optimized, which is crucial for patient safety.
The higher quality of diagnostics and lower number of unwarranted invasive procedures means:
- Lower healthcare costs,
- Earlier introduction of the right treatment,
- Reduction in the number of complications and hospitalizations.
Over the longer term, SYN2 may significantly reduce the financial burdens on healthcare systems, while improving the quality of patient care.
SYN2 has the potential to become the new standard in myocardial perfusion imaging, and to revolutionize how coronary artery disease is diagnosed.
Other competitive advantages of the SYN2 cardiotracer
From the perspective of the healthcare system, SYN2 enables broad implementation of PET/CT myocardial perfusion imaging (MPI) examinations, even at facilities that do not have their own cyclotron.
The half-life of fluorine-18 makes it possible to:
- Centralize production of the radiopharmaceutical,
- Efficiently transport it to numerous diagnostic facilities,
- Significantly reduce the entry barrier for perfusion testing centres.
The potential customers for SYN2 include both clinical hospitals and private diagnostic centres.
The deployment of cyclotrons in the regions where the company plans to operate is sufficient to significantly improve access to state-of-the-art PET/CT examinations, compared to preparations using isotopes with a much shorter half-life.
SYN2 is intended for a broad group of patients with suspected or increased risk of coronary artery disease, including people with high blood pressure, diabetes, high cholesterol, and the elderly. The growing number of patients in these risk groups translates into a large market potential for SYN2.
Additionally, the cardiotracer enables reliable imaging of patients who are hard to diagnosis, in whom adipose tissue in the chest, diaphragm or other anatomical structures interferes with the signal in traditional examinations. Thanks to this, SYN2 significantly improves the quality of diagnostics also in the most challenging groups of patients.